Real-world short-term VenaSeal ablation outcomes for symptomatic saphenous incompetence.

OBJECTIVE: Chronic venous insufficiency is a common vascular condition with significant resultant patient morbidity. There has been a shift towards minimally invasive treatment modalities with VenaSeal endovenous ablation among the more recent treatment modalities introduced. Long-term outcome data for this treatment modality is not widely available yet. We aim to report 6-week patient outcomes over a 5-year period from a high-volume tertiary vascular centre. METHODS: This is a retrospective, single-centre study reporting short-term outcomes following VenaSeal endovenous ablation for symptomatic saphenous incompetence. Patients were followed-up at 6-weeks post-procedurally by telemedicine or in-person clinic appointment without routine venous ultrasound assessment. RESULTS: We report outcomes for 235 patients during this study period. All patients tolerated the procedure under local anaesthesia. Average age was 60.5 years (29-82 years) with slight male predominance (55.7%). The majority were New Zealand European (63.8%). Mean body mass index was 28.5 (22.2-41.4). We report a 21% rate of self-limiting phlebitis and 33 minor complication events. These include 15 cases of residual varicose veins, 9 saphenous nerve neuropraxia, 6 cases of puncture-site cellulitis and 3 deep vein thromboses. Patient demographics and primary surgeon did not have a statistically significant outcome on development of complications. CONCLUSION: We report that VenaSeal endovenous ablation is a safe and effective method of treatment for symptomatic truncal saphenous vein incompetence. We report safely managing post-operative phlebitis conservatively and find a mixture of clinical and phone clinic follow-up sufficient without requirement for objective duplex ultrasound following the procedure to ensure objective saphenous vein closure.

Popliteal Artery Occlusion in a Sole Sciatic Arterial System Requiring Complex Repair.

Objective: Persistence of the sciatic artery is a rare phenomenon in vascular surgery. It results from abnormal embryologic development, and where present in the absence of a femoral arterial system, it can have significant clinical implications for patients and can even be limb threatening. We present the case of a 69-year-old man with left-sided, short-distance claudication and rest pain, which caused concern for critical limb ischaemia. Methods: Computed tomography angiography revealed a persistent sciatic artery arising from the common iliac artery and resulting in an occluded popliteal artery. The patient underwent a double-bypass procedure to restore the arterial supply to the symptomatic limb. A left iliopopliteal Dacron graft bypass was performed, followed by a left iliopopliteal Dacron to posterior tibial bypass using the patient's great saphenous vein. The left sciatic artery was ligated proximally. Results:This allowed for restoration of arterial supply to the patient's left lower limb, relieving his claudication and rest pain. Conclusion: The key finding was the aneurysmal nature of the sciatic artery, reflecting the likely thromboembolic nature of the distal popliteal disease. Thus, our patient required not only a bypass procedure but also ligation of the native sciatic artery. Timely management is critical due to severity of consequences.

Effect of Artery Diameter and Velocity and Vein Diameter on Upper Limb Arteriovenous Fistula Outcomes.

Objective: Haemodialysis is an important tool for end-stage renal disease (ESRD) patients to correct electrolyte disturbance and improve life quality. This requires a method of long-term vascular access. For many ESRD patients, arteriovenous fistula (AVF) formation is the optimal method of access. AVF success and patency are critical to allow access for haemodialysis. Failure to mature and thrombosis are key factors involved in AVF failure. Our aim is to report outcomes from a single-centre, retrospective study investigating the association between artery and vein measurements as well as intraoperative heparin use on autogenous upper limb AVF outcomes. Methods: This retrospective study analyses the influence of artery and vein diameter on AVF outcomes over a 12-month period, from 1 January 2019 through 31 December 2019. The key endpoint was AVF patency and functionality at 6 weeks postoperatively. Results: During our study period, 66 autogenous upper limb AVFs were formed in our tertiary vascular centre. This included 44 radiocephalic, 11 brachiocephalic, and 11 brachiobasilic AVFs. We report an association between minimum vein diameter >2.0 mm and arterial diameter >2.0 mm and AVF success and functionality. Our data did not support intraoperative heparin use as a measure to improve AVF success. Conclusion: This study suggests a statistically significant association between vein and artery diameter (>2.0 mm) with improved AVF patency at 6 weeks postoperatively. We did not observe benefit from intraoperative heparin use.

Inferior vena caval aneurysm diagnosed in context of trauma.

Inferior vena cava (IVC) aneurysms remain rare vascular entities that carry significant morbidity and potential mortality. Given the paucity of literature on this clinical entity, there is no consensus regarding management guidelines, and it is important to continue to add to the current literature body. In this report, we describe the case of a 64-year-old male diagnosed with a type III IVC aneurysm. Here, we describe this clinical presentation and discuss our management of this aneurysm in the context of the wider, yet limited literature body.

Effect of Systemic Intraoperative Heparin Use on Upper Extremity Arteriovenous Fistula Patency in End-Stage Renal Disease Patients.

The formation of the arteriovenous fistula is an important method of vascular access for patients with end-stage renal disease (ESRD). This allows renal filtration resulting in improved life quality and expectancy for ESRD patients. The biggest drawback to arteriovenous fistula formation is thrombosis, which can occur at an early or delayed stage. One suggested method of reducing postoperative arteriovenous fistula thrombosis rates is the administration of intraoperative systemic heparin. Heparin use in this context is debated, and there is currently no consensus on its use. There are a number of small randomised control studies trialling use of heparin but no large systematic trials. In this report, we collate existing evidence in the form of a review article and attempt to extrapolate a consensus of the evidence.

The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.

BACKGROUND AND AIM: New Zealand (NZ) has one of the highest rates of non-melanoma skin cancers (NMSCs) in the world. Thiopurine use in inflammatory bowel disease (IBD) patients has been shown to increase NMSC risk. This study aimed to investigate the possible increase of NMSC risk in thiopurine-treated IBD patients in NZ despite the high background rate. METHODS: Inflammatory bowel disease patients treated with thiopurines and healthy controls were recruited across two different latitude centers in NZ. Consented participants completed a questionnaire to identify additional risk factors and were examined for suspicious skin lesions. These were photographed, and the pictures were evaluated by a dermatologist. Data were compared between centers and between groups with NMSC incidence and thiopurine-associated relative risks estimated. RESULTS: One hundred seventy-one thiopurine-exposed IBD patients and 201 controls were recruited. Twenty seven of 390 photographs (26 participants) showed suspicious lesions (17 exposed, 9 controls) as determined by the dermatologist. Estimated NMSC incidence was 24.7-34.3/1000 patient-years (thiopurine-exposed, depending on classification of unconfirmed suspicious lesions) and 7-14/1000 patient-years (control). The relative risk of NMSC among thiopurine exposed was 2.38-2.97 (P ≤ 0.014), which remained significant after individually adjusting for potential confounders. We estimated the NMSC risk to increase 5.4-6.6% per 6 months of thiopurine use (P < 0.001). Low compliance in avoiding NMSC risk factors in the exposed group was observed. CONCLUSIONS: We found a twofold to threefold increase in NMSC incidence in IBD patients treated with thiopurines in NZ, despite the high background incidence rate.